Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410241 | 0.92 | IDO1 (0.43) | IDO1USP14 | |
| SCHEMBL3640129 | 0.90 | IDO1 (0.40) | IDO1USP14 | |
| SCHEMBL3640105 | 0.88 | IDO1 (0.39) | IDO1USP14 | |
| SCHEMBL14788135 | 0.87 | IDO1 (0.38) | IDO1USP14AGXT | |
| SCHEMBL16410239 | 0.85 | IDO1 (0.37) | IDO1USP14 | |
| SCHEMBL16410402 | 0.84 | IDO1 (0.36) | IDO1USP14 | |
| SCHEMBL16410320 | 0.84 | IDO1 (0.36) | IDO1USP14 | |
| SCHEMBL3407078 | 0.83 | USP14 (0.32) | IDO1USP14TACR1 | |
| SCHEMBL21551446 | 0.83 | IDO1 (0.36) | IDO1USP14TACR1 | |
| SCHEMBL30931820 | 0.83 | IDO1 (0.36) | IDO1USP14TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| CN-115916740-A | Thyromimetic agents | 速通医疗公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2021257851-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-8912223-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140200247-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | KARMALI RASHIDA A (US) | 2014-07-17 | — | — | US | disclosed |
| US-8377973-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377973-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | Tactical Therapeutics, Inc | 2011-03-10 | — | — | US | disclosed |
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | Tactical Therapeutics, Inc | 2011-03-10 | — | — | US | disclosed |
| EP-0151529-A2 | 5-(Amino or substituted amino)-1,2,3-triazoles | MERCK & CO. INC. (US) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | MCL1, MALT1, MYD88 | IDO1 690/4885USP14 2345/4885TACR1 4331/4885 |
| US-20230242471-A1 | THYROMIMETICS | TPO, THOP1, THRB | IDO1 568/4885USP14 2108/4885TACR1 777/4885 |
| US-20140200247-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | MCL1, MALT1, ABAT | IDO1 699/4885USP14 1994/4885TACR1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.